New Zealand markets closed

Hestia Insight Inc. (HSTA)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.44800.0000 (0.00%)
At close: 11:18AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.4480
Open0.4480
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.4480 - 0.4480
52-week range0.0300 - 0.7900
Volume2,500
Avg. volume107
Market cap27.346M
Beta (5Y monthly)0.91
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Hestia Insight Inc. Unveils Innovative Marketing Plan to Assist Emerging Companies

    LAS VEGAS, NV, Dec. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) ("Hestia Insight" and the “Company”), a company focused on the development and operation of novel technologies and providing marketing, management, business, and capital markets advisory services to its clients, today announced the launch of its new marketing plan - a strategic initiative designed to empower emerging growth companies by integrating professional expertise, top-tier talent, and AI

  • GlobeNewswire

    Hestia Insight Inc. Announces Upcoming Launch of AI-Powered IR Website Platform to Assist Start-Ups, Small and Medium Sized Companies

    NEW YORK, NY, Aug. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, and providing marketing, management, business, and capital markets advisory services to its clients within the healthcare and biotech sectors, today announced that in September 2023, its wholly owned subsidiary, Hestia Investments Inc. (“Hestia Inve

  • GlobeNewswire

    Hestia Insight Inc. Signs Letter of Intent With Leading Wound Care Company

    NEW YORK, NY, May 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced that it has entered into a Letter of Intent with RecentCare Biomedical, Inc., Taipei, Taiwan, (“RecentCare Biomedical”), a leading